About
Monoclonal Antibody
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
492
By Phase
PHASE1/PHASE2: 3PHASE2: 1PHASE1: 1
By Status
RECRUITING: 3TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07169734Lead Sponsor
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
PHASE1/PHASE2Recruiting
180 participants
Started: Aug 26, 2025 · Completed: Oct 4, 2029
NCT06747585Lead Sponsor
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
PHASE1/PHASE2Recruiting
170 participants
Started: Dec 16, 2024 · Completed: Aug 15, 2028
NCT06054477Lead Sponsor
Study of ALE.C04 in Patients With Head and Neck Cancer
PHASE1/PHASE2Terminated
21 participants
Started: Oct 30, 2023 · Completed: Feb 12, 2025
NCT06047171Lead Sponsor
Rescue of Nephrons With ALE.F02 (RENAL-F02)
PHASE2Recruiting
80 participants
Started: Sep 7, 2023 · Completed: Jun 30, 2027
NCT05939947Lead Sponsor
A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
PHASE1Completed
41 participants
Started: Apr 1, 2023 · Completed: Oct 30, 2024
Locations (1)
Headquarters
Allschwil, Switzerland
Map
Loading map...